Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Lee DW, Lee KH, Kim HJ, et al. A phase ii trial of s-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. Bmc Cancer. 2018;18(1):252.
   PubMedGoogle Scholar
• European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. Easl-eortc clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the japan society of hepatology (2009). Hepatol Res. 2010;40(7):667–685.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: jsh-lcsgj criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31.
   PubMedGoogle Scholar
• Arizumi T, Ueshima K, Chishina H, et al. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the lcsgj. Oncology. 2014;87(Suppl 1):32–36.
   PubMedGoogle Scholar
• Qiu Z, Shen L, Chen S, et al. Efficacy of apatinib in transcatheter arterial chemoembolization (tace) refractory intermediate and advanced-stage hepatocellular carcinomaa propensity score matching analysis.Cancer Manag Res. 2019;11:9321–9330.
   PubMed Web of Science ®Google Scholar
• Wu J, Li A, Yang J, et al. Efficacy and safety of tace in combination with sorafenib for the treatment of tace-refractory advanced hepatocellular carcinoma in chinese patients: a retrospective study. Onco Targets Ther. 2017;10:2761–2768.
   PubMed Web of Science ®Google Scholar
• Kodama K, Kawaoka T, Aikata H, et al. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33(10):1780–1786.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (tace) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4(4):253–262.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a european perspective. Liver Cancer. 2014;3(2):119–124.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Nccn guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563–573.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shen L, Zhao L, et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in bclc stage b hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(4):219–224.
   PubMed Web of Science ®Google Scholar
• Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28(3):456–463.
   PubMed Web of Science ®Google Scholar
• Hu H, Chen GF, Yuan W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia. 2018;34(8):1351–1358.
   PubMed Web of Science ®Google Scholar
• Liu C, Liang P, Liu F, et al. Mwa combined with tace as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27(7):654–662.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–432.
   PubMed Web of Science ®Google Scholar
• Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2004;39(3):205–214.
   PubMed Web of Science ®Google Scholar
• Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in japan: consensus-based clinical practice guidelines proposed by the japan society of hepatology (jsh) 2010 updated version. Dig Dis. 2011;29(3):339–364.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol. 2014;49(5):932–940.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus tace with doxorubicin-eluting beads for intermediate stage hcc: the space trial. J Hepatol. 2016;64(5):1090–1098.
   PubMed Web of Science ®Google Scholar
• Ni JY, Sun HL, Chen YT, et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol. 2014;20(46):17483–17490.
   PubMed Web of Science ®Google Scholar
• Zhang TQ, Huang ZM, Shen JX, et al. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. Therap Adv Gastroenterol. 2019;12:175628481986296–175628321915466.
   Web of Science ®Google Scholar
• Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas. Korean J Radiol. 2018;19(2):237–246.
   PubMed Web of Science ®Google Scholar